POZ Community Forums
Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: hahaha on July 30, 2007, 05:33:09 am
-
Neovacs is currently developing a broad portfolio of several promising therapeutic vaccines based on its patented, active anti-cytokine and anti-viral protein immunization technologies. Two products have already been tested in clinical trials: Tat toxoid, Neovacs' first anti-HIV therapeutic vaccine, and interferon alpha (IFN?) kinoid, a cytokinic immunogen which induces the production of neutralizing anti-interferon ? antibodies. The latter has been assessed in pilot clinical trials where induction of neutralizing anti-IFN? antibodies was observed in around 200 HIV-infected patients, with good long-term tolerance. The interferon ? kinoid is currently being studied in murine models of systemic lupus erythematosus, with positive results having been presented at the 8th International Congress on Lupus which took place from May 23rd – 27th 2007 in Shanghai (China). Two other products, TNF? kinoid and VEGF kinoid, are due to enter clinical trials following promising results in animal models of rheumatoid arthritis and certain cancers. These results were recently described in articles published in the prestigious journal PNAS ("TNF alpha kinoid vaccination-induced neutralizing antibodies to TNF alpha protect mice from autologous TNFalpha-driven chronic and acute inflammation", Le Buanec H. et al. (2006) PNAS 103:19442-19447; "VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastasis" Haghighi Rad F. et al. (2007) PNAS 104:2837-2842).